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Nucleoside transporter proteins are specialized proteins that mediate the transport of nucleosides and nucleoside analog drugs across
the plasma membrane. The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular
entry of gemcitabine, cytarabine, and fludarabine. The hENT1 expression has been demonstrated to be related with prognosis and activity
of gemcitabine-based therapy in breast, ampullary, lung, and pancreatic cancer. We investigated the immunohistochemical expression of
hENT in tumor samples from 111 patients with resected gastric adenocarcinoma, correlating these data with clinical parameters and
disease outcomes. None of the patients received chemotherapy or radiation therapy before or after surgery as a part of an adjuvant or
neoadjuvant program. On univariate survival analysis, the hENT1 expression was associated with overall survival (OS) and disease free
survival (DFS). Specifically, those patients with overexpression of hENT1 showed a shorter OS (P¼ 0.021) and a shorter DFS (P¼ 0.033).
Considering only the node positive patients, higher hENT levels were associated with significantly shorter median DFS (21.7 months; 95%
CI 11.1–32.4) compared with patients with low expression of hENT1. The hENT1 expression was defined, in the lymph-node positive
patients, as an independent prognostic factor (P¼ 0.019). Furthermore, considering only patients with diffuse or mixed tumors and
lymph-node positive, the expression of hENT1 was strongly related with DFS and OS. Immunohistochemistry for the hENT1 protein
carries prognostic information in patients with resected gastric cancer and holds promise as a predictive factor in chemotherapy decisions.
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DOI: 10.1002/jcp.22045Gastric cancer is an aggressive disease. The prognosis of
patients remains poor even after radical surgery, because of
the unpredictability of the disease and the lack of effective
complementary treatments (Ono, 2006). Many molecular
prognostic factors based on the biological characteristic of
gastric cancer have been proposed in the last few years, but
studies based on larger and more homogeneous series of
patients are necessary before any of these biological marker can
be used in the routine clinical setting for the identification of
patients at higher risk of recurrence that could benefit more
from adjuvant chemotherapy (Nitti et al., 2008). DNA-ploidy
heterogeneity in gastric cancers is also under evaluation as
prognostic factor in gastric cancer. To date there is no generally
accepted adjuvant chemotherapy for patients with radically
resected gastric cancer (Di Costanzo et al., 2008). In advanced
gastric cancer the combination between gemcitabine and
fluoropyrimidine has been tested, in consideration of the
properties of gemcitabine that has shown to enhances the
anti-tumor activity of 5-FU.
Nucleoside transporter proteins are specialized proteins
that mediate the transport of nucleosides and nucleoside analog
drugs across the plasma membrane. This step is necessary for
the pharmacological action of these drugs (Molina-Arcas et al., 2 0 1 0 W I L E Y - L I S S , I N C .2008). The human equilibrative nucleoside transporter 1
(hENT1), the most abundant and widely distributed plasma
membrane nucleoside transporter in human cells, is a member
of these proteins and mediates cellular entry of gemcitabine,
cytarabine, and fludarabine (Giovannetti et al., 2006b; Zhang
et al., 2007). In fact deficiency in hENT1 confers resistance to
toxicity and efficacy of these drugs in many in vitro models
of hematologic (Tallman, 2005; Cai et al., 2008; Lai et al., 2008)
and solid tumors (Mackey et al., 1998; Seve et al., 2005;
Cano-Soldado et al., 2008). Kinetic studies of human cell
lines with defined nucleoside transporter processes have
demonstrated that gemcitabine intracellular uptake is mediated
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demonstrated that ENT1-deficient cells are resistant to
cytotoxic nucleosides in vitro (Gati et al., 1998). With the
advent of molecular and immunologic probes for nucleoside
transporter proteins, the differential expression of nucleoside
transporters in normal and tumor tissue has been studied
(Pennycooke et al., 2001; Dabbagh et al., 2003).
The abundance and distribution of the hENT1 protein can be
evaluated using immunohistochemistry and has been assessed
in a number of malignant and benign tissues (Mackey et al., 2002;
Chow et al., 2005). Recent data indicate that a high expression
of hENT1 is a poor prognostic factor in patients with metastatic
and resected pancreatic cancer, even if, on multivariate analysis,
it is associated with a longer survival, disease-free survival and
time to disease progression in patients treated with
gemcitabine (Giovannetti et al., 2006a). The identification of
high levels of hENT1 represents a positive predictive factor of
response to gemcitabine not only in patients with advanced
pancreatic cancer (Spratlin et al., 2004), but also in patients with
resected disease (Farrell et al., 2007) and with metastatic lung
disease (Seve et al., 2005). Recently, our group has
demonstrated that hENT1 expression is a molecular prognostic
marker for patients with resected ampullary cancer, identifying
a patient population with poor prognosis that could benefit
from nucleoside analog treatment (Santini et al., 2008). On the
basis of these findings, we studied the expression of hENT in
tumor samples from 111 patients with resected gastric
adenocarcinoma, correlating these data with clinical
parameters and disease outcomes.
Materials and Methods
Clinical data and tumor sample acquisition
This retrospective study targeted a high-risk population of
stage II–III gastric cancer patients. A consecutive series of patients
from the referral population of a regionally based cancer service
were considered. Tissues were collected from patients undergoing
gastric surgical resection with curative intent surgery at the
Azienda Ospedale San Salvatore (Pesaro, Italy). Only patients
without known residual disease were analyzed. One hundred
eleven patients with stage II–III disease, which was treated with R0
surgery and D1–D2 lymphoadenectomy (>10 retrieved lymph
nodes) (McShane et al., 2005) were included. Data on clinical
variables, including sex, age, preoperative assessment of disease
status, and type of operative procedure were gathered
retrospectively from patient records. A minimum of 3-year follow-
up was required. Follow-up procedures consisted of interim
history, physical examination, hematologic evaluation,
carcinoembryonic antigen levels, gastrointestinal cancer antigen
(GICA), and diagnostic imaging (chest X-ray and abdominal
ultrasonography) every 4 months in the first year and every
6 months thereafter. Patients underwent upper endoscopy
6 months after surgery and every 12 months thereafter.
Whole-body computed tomography was performed for
corroborative evidence of relapse. The recurrences of gastric
adenocarcinoma had to be confirmed by cytology, biopsy, or
surgery. Pathological findings (tumor size, spread, and lymph-node
status) were obtained from the pathologists’ original reports.
Tumor–node–metastasis status (TNM) classification was
reassessed using the 1997 revision of the AJCC manual. None of
the patients received chemotherapy or radiation therapy before
or after surgery as a part of an adjuvant or neoadjuvant program.
Survival was determined from the date of initial surgery to the date
of death or last contact. Follow-up data were available for all
included patients. The study was conducted in a blinded fashion
so that patients’ outcomes were unknown to investigators
performing immunohistochemistry analyses. The study was carried
out with approval of the relevant local institutional research
boards.JOURNAL OF CELLULAR PHYSIOLOGYTissue preparation and immunostaining
Representative tumor blocks were sectioned at 3-mm thickness for
immunohistochemical studies. The sections were deparaffinized
with three immersions in xylene baths (10 min each) followed by
serial washes in graded alcohol from 100% to 50%. After rinsing in
water, slides were placed in 250 ml of high pH 1 DAKO target
antigen retrieval solution and microwaved in TT-mega Milestone
(ESBE Scientific, Markham, Ontario, Canada) under controlled
temperature and high pressure for 10 min at 1008C. After cooling
in water for 6 min, slides were rinsed with water and peroxidase
blocked in 3% hydrogen peroxide solution with methanol for
10 min then washed in running water for 10 min. Phosphate-
buffered saline (PBS) (pH 7.2) was used for rinsing before
incubation in a humidified chamber overnight at 48C with
appropriate dilutions of anti-hENT1 mouse mAb developed and
characterized as described previously [23]. The sections were then
rinsed with PBS, immersed in buffer for 5 min, and incubated with
goat anti-mouse dextran conjugate (DAKO Envision) for 30 min
followed by soaking in PBS. DAKO diaminbenzidine liquid
chromogen was placed on the samples for 5 min and rinsed, after
which, the slides were soaked in 1% CuSO4 for another 5 min.
Subsequently, the sections were rinsed, counterstained with
hematoxylin, dehydrated through graded alcohol and xylene, and
finally coverslipped. Negative controls were provided by omitting
the primary antibodies. Positive internal controls were provided by
evaluation of tissue lymphocytes [21] and endothelial cells [24] as
previously demonstrated. These internal controls were then used
as internal reference for the evaluation of relative intensities of
stain. In particular, endothelial cell staining was observed and
assigned a score of 2þ and the staining of invasive adenocarcinoma
cells was graded as follow: absent (0), definite positive but less
intense than internal control tissue (1þ), positive-like internal
control tissue (2þ), and positive, more intense than internal
control tissue (3þ). Samples with regions of varying staining
intensities of hENT1 were scored and the percentages of each
staining intensity were recorded. Finally, tumors with an intensity
staining of 2þ and 3þ in more than 50% of the tumor cells were
considered as strong expression of hENT1.
Immunostaining was assessed by two independent pathologists
blinded to clinical characteristics and outcomes. In case of different
assessment for single case, a third pathologist scored the sample in
a blinded way.
Statistical analysis
A univariate survival analysis for each prognostic variable on overall
survival (OS) and disease free survival (DFS) was estimated as by
the Kaplan–Meier method (Kaplan and Meier, 1958). The terminal
event was death, attributable to cancer or non-cancer causes for
OS and clinical detectable progression of disease according to
RECIST criteria for DFS. The statistical significance of the
differences in survival distribution among the prognostic groups
was evaluated by the log-rank test (Peto et al., 1977). The Cox
proportional hazards model was applied to the multivariate survival
analysis (Cox, 1972). The prognostic variables for OS and DFS
included grading, T and N factors, stage and hENT1 expression
values<0.05 were regarded as statistically significant in two-tailed
tests. SPSS software (Version 13.00, SPSS, Chicago, IL) was used for
statistical analysis.
Results
Patient characteristics
The main clinicopathological features of the 111 studied
patients are summarized in Table 1. Median age was 72 years
(range 36–88); 53 were males and 58 females. Seventy-nine
(71.2%) patients had locoregional lymph-node metastasis.
Forty-seven (42.3%) patients had stage II disease, whereas
57.7% had stage III. In this study, 48 patients (43.2%) died with
TABLE 1. Patients’ characteristics
Total number 111
Age (years)
Median (minimum–maximum) 72 (36–88)
Gender: number (%)
Male 53 (47.8%)
Female 58 (52.2%)
Gastrectomy: number (%)
Total 79 (71.2%)
Partial 32 (28.8%)
Histology: number (%)
Diffuse 27 (24.3%)
Intestinal 68 (61.3%)
Mixed 15 (14.4%)
Stage: number (%)
2 47 (42.3%)
3 64 (57.7%)
Grading: number (%)
Well differentiated 6 (5.4%)
Moderately differentiated 59 (53.1%)
Poorly differentiated 46 (41.5%)
Pathologic tumor status
pT2 21 (18.9%)
pT3 88 (79.2%)
pT4 2 (1.9%)
Lymph-node status: number (%)
Positive 79 (71.2%)
Negative 32 (28.8%)
Percentage of positive nodes
Median (minimum–maximum) 9.3 (0–87.5)
Relapse: number (%)
No 58 (52.2%)
Yes 53 (47.8%)
Death: number (%)
No 63 (56.7%)
Yes 48 (43.3%)
386 S A N T I N I E T A L .positive cytological or histological confirmation of recurrent
disease. All 48 relapsed patients underwent 5-fluorouracil/
cisplatin-based palliative chemotherapy. Median follow-up after
surgery was 5.5 years (range 3–8.5 years). After this follow-up,
58 patients (52.5%) are still alive without evidence of
recurrence, 5 patients (4.5%) are alive with recurrence of
disease, and 48 patients (43%) are dead for cancer recurrence.
Clinicopathological characteristics and
patients’ outcome
In our cohort of patients a significantly improved OS was
observed in patients with low-grade (P¼ 0.002), low T
(P¼ 0.041), N negative tumors (P¼ 0.020), and low tumorFig. 1. Correlation between hENT expression and DFS (A) and OS (B).
www.interscience.wiley.com.]
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correlation was also found between grading (P¼ 0.002),
N status (P¼ 0.022), tumor stage (P¼ 0.001), and DFS on
univariate analysis (Kaplan–Meyer curves not shown).
hENT1 staining
The immunohistochemical hENT1 staining was present within
tissue lymphocytes and endothelial cell, as previously reported,
and were used as internal positive controls. The localization of
the hENT1 immunostaining was predominantly membrane,
although occasional cytoplasmic staining was seen. The normal
gastric mucosa and the peritumoral stroma cells were
otherwise negative. Of the 110 tumor specimens, 50 (45.4%)
specimens had high hENT1 immunostaining (intensity scores
>50%), while 60 (54.5%) samples were classified as low hENT1
immunostaining (intensity scores 50%). Of 68 intestinal type
gastric cancers, 30 (44.1%) were classified as high hENT1
immunostaining patients. Of 27 diffuse type cancers, 7 (25.9%)
were classified as high hENT1 immunostaining patients.
Correlation between clinical outcomes and
hENT1 staining
To establish the prognostic role of hENT1, patients were
stratified in positive (hENT-high expression) versus negative
(hENT-low expression). On univariate survival analysis, the
hENT1 expression was associated with OS and DFS.
Specifically, those patients with overexpression of hENT1
showed a shorter OS (P¼ 0.021) and a shorter DFS (P¼ 0.033;
Fig. 1).
hENT1 staining and survival: Subgroup analysis
After having established that hENT1 is a negative prognostic
factor in all patients, we evaluated if the expression of hENT
have a role also in the subsets of patients with poor prognosis.
Of the 111 patients, 79 (71.2%) of the patients were
lymph-node positive. Considering only these patients, we
demonstrated on univariate survival analysis that higher hENT
levels were associated with significantly shorter median DFS
(21.7 months; 95% CI 11.1–32.4, Fig. 2) compared with patients
with low expression of hENT1 (median DFS not reached).
These results were confirmed on multivariate analysis, in fact
the hENT1 expression was defined as an independent
prognostic factor (P¼ 0.019, Table 2). In lymph-node positive
patients, a correlation between hENT1 levels and OS was also[Color figure can be viewed in the online issue, which is available at
Fig. 2. Correlation between hENT expression and DFS in lymph-
node positive patients: univariate analysis. [Color figure can be
viewed in the online issue, which is available at www.interscience.
wiley.com.]
Fig. 3. Correlation between hENT expression and OS in lymph-
node positive patients: univariate analysis. [Color figure can be
viewed in the online issue, which is available at www.interscience.
wiley.com.]
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patients had a shorter median OS (31.533 months; 95% CI 10,
295–11.355, Fig. 3) in comparison to hENT-negative patients
(median OS not reached). Our findings from the multivariate
analysis demonstrated that the hENT-1 expression was also a
strong independent predictor of OS (P¼ 0.017, Table 3).
Conclusions
There are few substantial data reporting significant biological
prognostic markers for gastric cancer patients. The influence of
pathologic (tumor stage, lymph-node involvement, status of
resection margins) and surgical (aggressive surgical approach on
lymph nodes versus limited resection) factors is clear
(Kirkwood et al., 1997). There is, in radically resected gastric
cancer, substantial interest in identifying and validating
molecular markers to select patients with a high likelihood of
benefiting from specific chemotherapy regimens. Gemcitabine,
a nucleoside chemotherapy drug used in many solid tumors,
requires the nucleoside transporter protein hENT1 to
efficiently enter cells (Mackey et al., 1998), and hENT1
deficiency confers resistance to gemcitabine in vitro (Mackey
et al., 1999). Moreover, hENT1 plays an important role in 5-FU
resistance in vitro (Tsujie et al., 2007). Recently, the
immunohistochemical assessment of the nucleosideTABLE 2. Multivariate analysis of DFS in lymph-node positive patients
Relative risk 95% Confidential interval P
DFS
Grading
1–2 1 — 0.027
3 1.946 1.21–2.99
Histology
Intestinal 1 — 0.445
Diffuse-mixed 1.210 0.83–1.86
HENT-1
0 1 — 0.019
1 2.125 1.18–3.78
JOURNAL OF CELLULAR PHYSIOLOGYtransporter protein hENT1 has shown both prognostic and
predictive value in the setting of adenocarcinoma of the
pancreas and of lung cancer treated with the nucleoside
chemotherapy drug, gemcitabine (Mackey et al., 2002; Chow
et al., 2005; Seve et al., 2005). For these reasons, we
characterized the pattern of expression to explore the possible
prognostic significance of hENT1 expression in a homogeneous
cohort of patients with radically resected gastric cancer. Similar
to the previous description of hENT1 in pancreatic carcinoma
(Chow et al., 2005) immunohistochemical identification of the
hENT1 protein in gastric cancer tissue revealed two patterns of
staining, either (a) positive staining of adenocarcinoma cells or
(b) regions lacking hENT1 in a proportion of adenocarcinoma
cells.
Internal controls for this assessment were provided by
positively staining endothelial cells and lymphocytes. In this
cohort of patients we demonstrated that 45.4% of specimens
had high hENT1 immunostaining (intensity scores 2–3þ in
>50%), while 54.5% of samples possessed a low or absent
hENT1 immunostaining (intensity scores 2–3þ in 50%). Our
hypothesis is that at least one half of patients may have a higher
probability to benefit from gemcitabine-based and
fluoropyrimidine-based chemotherapy. However, further
studies with gemcitabine/fluoropyrimidines-treated gastric
carcinoma assessed for hENT1 immunostaining will be requiredTABLE 3. Multivariate analysis of OS in lymph-node positive patients
Relative risk 95% Confidential interval P
OS
Grading
1–2 1 — 0.027
3 1.944 1.20–3.28
Histology
Intestinal 1 — 0.445
Diffuse-mixed 1.629 0.78–2.90
HENT-1
0 1 — 0.017
1 2.160 1.29–4.16
388 S A N T I N I E T A L .to evaluate this hypothesis. This study clearly showed that high
immunohistochemical staining for the hENT1 protein is
significantly correlated with poor prognosis, in term of OS and
DFS, in patients with radically resected gastric cancer.
Moreover, considering only positive node patients, higher
hENT levels were associated with significantly shorter median
DFS and OS. These results were confirmed on multivariate
analysis, in fact the hENT1 expression was defined as an
independent prognostic factor for DFS and OS (respectively,
P¼ 0.019 and 0.017). In the node positive subset of patients
hENT1 expression could represent also a predictive factor for
response to gemcitabine/fluoropyrimidines-based
chemotherapy in adjuvant setting. These findings warrant the
consideration of prospective trials of gemcitabine/
fluoropyrimidines based chemotherapy in resected gastric
carcinoma, with tissue assessment to define the relationship
between hENT1 immunohistochemical staining and clinical
outcomes. Furthermore, gemcitabine and fluorouracil or
capecitabine may be of particular benefit in those patients with
metastatic or recurrent disease expressing high levels of hENT1
in tumor samples. In conclusion, immunohistochemistry for the
hENT1 protein carries prognostic information in patients with
resected gastric cancer and holds promise as a predictive factor
to assist in chemotherapy decisions. Moreover, these findings
will be validated using also other modalities.
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